Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study
Toripalimab plus Gemcitabin und Cisplatin als Induktionschemotherapie beim lokal fortgeschrittenen Nasopharynxkarzinom: retrospektive Studie
Frontiers in Oncology · 24.11.2025 · 15
DOI: 10.3389/fonc.2025.1704442 ↗Auf einen Blick
Bei 105 Patient:innen mit LANPC war Toripalimab plus GP mit einer höheren Komplettremissionsrate und besserem 2-Jahres-EFS verbunden als GP allein. Die Toxizität war ähnlich.
Fragestellung
Verbessert Toripalimab zusätzlich zu Gemcitabin/Cisplatin und anschließender Radio-/Chemoradiotherapie die Wirksamkeit und Sicherheit bei LANPC?
Methode
Retrospektive Analyse von 105 Patient:innen mit LANPC von Dezember 2019 bis Dezember 2022; 50 erhielten GP, 55 Toripalimab plus GP; alle erhielten Radiotherapie oder CCRT mit Cisplatin.
Ergebnisse
Nach Induktion CR: 30,9 % (17/55) vs. 12,0 % (6/50), p=0,019. 2-Jahres-EFS: 98,1 % vs. 85,4 %; HR 0,28 (95 %-KI 0,08–0,97), p=0,024. Grad 3–4 AEs: 47,3 % vs. 58,0 %.
Schlussfolgerung der Autor:innen
Die Zugabe von Toripalimab zu GP-Induktionschemotherapie verbesserte das EFS signifikant, ohne die Toxizität zu erhöhen.
Kernaussagen
- CR nach Induktion höher mit Toripalimab plus GP: 30,9 % vs. 12,0 %
- 2-Jahres-EFS besser: 98,1 % vs. 85,4 %; HR 0,28
- Grad 3–4 AEs traten in beiden Gruppen ähnlich häufig auf
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.11.2025. Verfasst von Renba Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Ac…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To explore the efficacy and safety of toripalimab combined with gemcitabine and cisplatin (GP) induction chemotherapy and sequential concurrent chemoradiotherapy in LANPC treatment.
Methods
This was a retrospective analysis of 105 patients with LANPC from December 2019 to December 2022. In total, 50 patients received two or three cycles of GP induction chemotherapy and 55 patients received toripalimab plus GP. Toripalimab (240 mg) was given intravenously on the first day of each cycle of induction chemotherapy. All patients received radiotherapy or concurrent chemoradiotherapy with cisplatin.
Results
After induction therapy, 17 (30.9%) patients in the GP plus toripalimab group and 6 (12.0%) in the GP alone group achieved complete response (CR) (p=0.019). After a median follow-up of 38.6 months, 16.0% (8/50) of the patients in the GP group and 3.6% (2/55) of the patients in the toripalimab plus GP group experienced recurrence or metastasis. There were 2 deaths in the GP group and no deaths in the toripalimab plus GP group. The 2-year event-free survival (EFS) rate was higher in the toripalimab plus GP group than in the GP group (98.1% vs. 85.4% (HR, 0.28; 95% confidence interval [CI], 0.08–0.97; p=0.024)). The 2-year overall survival, locoregional relapse-free survival and distant metastasis-free survival rates for toripalimab plus GP vs. GP alone were 100.0% vs. 100.0% (p=1.00), 98.1% vs. 89.5% (p=0.086), and 100.0% vs. 95.9% (p=0.15), respectively. Grade 3–4 adverse events (AEs) occurred in 26 (47.3%) and 29 (58.0%) patients in the toripalimab plus GP and GP alone arms, respectively. The most common grade 3–4 AEs were neutropenia (20 [36.4%] vs. 21 [42.0%]), leukopenia (18 [32.7%] vs. 17 [34.0%]), and vomiting (15 [27.3%] vs. 12 [24.0%]) in the toripalimab plus GP arm compared with the GP alone arm. Immune-related AEs of grade 3–4 occurred in three (5.5%) patients in the toripalimab plus GP arm.
Conclusions
The addition of toripalimab to GP induction chemotherapy significantly improves EFS without increasing toxicity in LANPC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
- Department of Radiation Oncology, Shenzhen Luohu People's Hospital, Shenzhen, China.
Zitieren
APA
Liang, R., Lei, L., Li, X., Lan, F., Fu, F., Zou, T., Ma, L., Chen, P., Wang, Z., Jin, J., & Zhang, J. (2025). Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1704442
Vancouver
Liang R, Lei L, Li X, Lan F, Fu F, Zou T, et al. Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1704442
BibTeX
@article{Liang2025,
author = {Liang, Renba and Lei, Ling and Li, Xinxiao and Lan, Fengming and Fu, Fangmeng and Zou, Teng and Ma, Li and Chen, Peng and Wang, Zhanmei and Jin, Jing and Zhang, Jianghu},
title = {Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1704442}
}
EUVIMED